IP Library › Patent Application 18476921
Patent Application
App. No. 18/476,921

MERS-CoV Vaccine

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/476,921
Abstract

Disclosed herein is a vaccine comprising a Middle East Respiratory Syndrome coronavirus (MERS-CoV) antigen. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.

Claims (17)

1 .- 35 . (canceled)

36 . A peptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence comprising a fragment of SEQ ID NO:2 lacking the IgE leader sequence as set forth in SEQ ID NO:6; and

b) an amino acid sequence comprising a fragment of SEQ ID NO:4 lacking the IgE leader sequence as set forth in SEQ ID NO:6.

37 . A method of inducing an immune response against a Middle East Respiratory Syndrome coronavirus (MERS-CoV) in a subject in need thereof, the method comprising administering to the subject an immunogenic composition comprising a peptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence comprising a fragment of SEQ ID NO:2 lacking the IgE leader sequence as set forth in SEQ ID NO:6; and

b) an amino acid sequence comprising a fragment of SEQ ID NO:4 lacking the IgE leader sequence as set forth in SEQ ID NO:6.

38 . The method of claim 37 , wherein administering includes at least one of electroporation and injection.

39 . A method of protecting a subject in need thereof from infection with a Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering to the subject an immunogenic composition comprising a peptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence comprising a fragment of SEQ ID NO:2 lacking the IgE leader sequence as set forth in SEQ ID NO:6; and

b) an amino acid sequence comprising a fragment of SEQ ID NO:4 lacking the IgE leader sequence as set forth in SEQ ID NO:6.

40 . The method of the claim 39 , wherein administering includes at least one of electroporation and injection.

41 . A method of treating a subject in need thereof against Middle East Respiratory Syndrome coronavirus (MERS-CoV), the method comprising administering to the subject, an immunogenic composition comprising a peptide comprising an amino acid sequence selected from the group consisting of:

a) an amino acid sequence comprising a fragment of SEQ ID NO:2 lacking the IgE leader sequence as set forth in SEQ ID NO:6; and

b) an amino acid sequence comprising a fragment of SEQ ID NO:4 lacking the IgE leader sequence as set forth in SEQ ID NO:6,

 wherein the subject is thereby resistant to one or more MERS-CoV strains.

42 . The method of claim 41 , wherein administering includes at least one of electroporation and injection.